Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

Written by Customer Service on May 19, 2023. Posted in Public Companies.

MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration’s (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) is meeting today to review obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH). The Advisory Committee meeting is scheduled for 9:00 a.m. – 5:00 p.m. ET. The briefing materials can be found on the FDA website (click here). As previously reported, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 22, 2023. The timeline...

First Ever NFT as a Movie, Zero Contact Starring Anthony Hopkins Goes Global at Cannes Film Festival

Written by Customer Service on May 19, 2023. Posted in Public Companies.

Filmed in 17 Different Countries, Including the First Scripted Feature Ever to Film in Antarctica, Hits Cannes Film Festival to Distribute the Film Internationally through Opus One Pictures Fairfield, CA., May 19, 2023 (GLOBE NEWSWIRE) — MetaWorks Platforms, Inc. (“MetaWorks” or the “Company”), (CSE: MWRK and OTCQB: MWRK), an award-winning Web3 company that owns and operates blockchain platforms in the entertainment & technology space, today announced that, on the heels of its agreement to sell the International rights of the film ZERO CONTACT, the world’s first ever full length feature film to be launched as an NFT, the movie is now being offered for distribution in all 17 of the countries the film was produced in through its deal with Opus One Pictures at the Cannes Film Festival. ZERO CONTACT made film history by becoming...

TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab

Written by Customer Service on May 19, 2023. Posted in Public Companies.

Company prioritizes education with a variety of in-person and virtual training programs MALVERN, Pa., May 19, 2023 (GLOBE NEWSWIRE) — TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced it will be hosting its next cadaver lab on May 19 in Tampa, Florida. The upcoming program, “Advanced Hernia Repair with OviTex® Reinforced Tissue Matrix,” will provide surgeons the opportunity to learn innovative open and robotic-assisted hernia repair techniques. TELA Bio has partnered with key opinion leaders in general and plastic and reconstructive surgery to develop a series of interactive medical education programs focused on the safe and effective...

Virtu Financial Congratulates Helen Ren, Recipient of the Rising Star Award at Women in Finance Asia

Written by Customer Service on May 19, 2023. Posted in Public Companies.

NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NASDAQ: VIRT) a leading provider of financial services and products that leverage cutting-edge technology to deliver innovative, transparent trading solutions to our clients and liquidity to the global markets, is pleased to congratulate and recognize Helen Ren for being awarded the Rising Star award at Markets Media’s Women in Finance Asia Awards. The prestigious award recognizes women who have made a significant contribution to the financial industry with their entrepreneurial spirit and leadership. “I am thrilled to see Helen recognized with the Rising Star award. It is a testament to her hard work, collegiality, and exceptional performance,” said Steve Cavoli, Global Head of Execution Services at Virtu Financial. “She’s an asset to our team, and I am so proud...

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

Written by Customer Service on May 19, 2023. Posted in Public Companies.

KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small molecule inhibitors in development for the treatment of liquid and solid tumors Company plans to share initial safety and proof-of-mechanism clinical data in second half of 2023 WATERTOWN, Mass., May 19, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, has recently dosed the first patient in the Phase 1 multicenter, open-label, dose-escalation clinical trial evaluating its investigational MDM2 degrader KT-253. The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and clinical activity of ascending...

Bilibili Inc. to Report First Quarter 2023 Financial Results on Thursday, June 1, 2023

Written by Customer Service on May 19, 2023. Posted in Public Companies.

Earnings Call Scheduled for 8:00 a.m. ET on June 1, 2023 SHANGHAI, China, May 19, 2023 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it will report its first quarter 2023 unaudited financial results on Thursday, June 1, 2023, before the open of U.S. markets. The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on June 1, 2023 (8:00 PM Beijing/Hong Kong Time on June 1, 2023). Details for the conference call are as follows: Event Title: Bilibili Inc. First Quarter 2023 Earnings Conference Call Registration Link: https://register.vevent.com/register/BI97fa686598904dc99838229131aefe79 All participants must use the link provided above to...

Medallion Financial Corp. to Participate in Upcoming Investor Conference

Written by Customer Service on May 19, 2023. Posted in Public Companies.

NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) — Medallion Financial Corp. (NASDAQ: MFIN, “Medallion” or the “Company”), a specialty finance company that originates and services loans in various consumer and commercial industries, along with offering loan origination services to fintech strategic partners, announced today it will participate in the upcoming 23rd Annual B. Riley Securities Institutional Investor Conference. 23rd Annual B. Riley Securities Institutional Investor Conference The Conference will take place at the Beverly Hilton Hotel May 24-25, 2023 MFIN management will participate in a fireside chat on Wednesday, May 24 from 8:15 a.m. until 8:55 a.m. PT MFIN management will also be available for one-on-one meetings throughout the conference. For more information about the conference or to schedule a one-on-one meeting with...

Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference

Written by Customer Service on May 19, 2023. Posted in Public Companies.

MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the 2023 American Thoracic Society (ATS) International Conference, taking place May 19-24, 2023, in Washington, D.C. Thematic Poster Session: B64 – The Multiple Components of Pulmonary Rehabilitation Date and time: Monday, May 22, 2023, 11:30 a.m. – 1:15 p.m. ETLocation: Area J, Hall C (Lower Level), Walter E. Washington Convention CenterPresenting Author: Charles Burger, M.D., from the Mayo Clinic, Jacksonville, FloridaAbstract: Exploratory Efficacy Analysis of INSPIRE Open Label Extension Study with Inhaled Treprostinil (Yutrepia™) Following the presentation, the...

Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update

Written by Customer Service on May 19, 2023. Posted in Earnings Releases And Operating Results.

Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and Simponi Aria® (golimumab) initiated, marking the fifth internally developed portfolio candidate to be dosed in a patient study Satisfactory outcome of facility reinspection remains the key requirement for U.S. approval of Biologics License Applications (BLAs) for AVT02, a proposed high-concentration, interchangeable biosimilar to Humira® (adalimumab) Management will conduct a business update conference call and live webcast on Friday, May 19, 2023, at 8:00 am ET (13:00 pm GMT) Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update

Written by Customer Service on May 19, 2023. Posted in Earnings Releases And Operating Results.

Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and Simponi Aria® (golimumab) initiated, marking the fifth internally developed portfolio candidate to be dosed in a patient study Satisfactory outcome of facility reinspection remains the key requirement for U.S. approval of Biologics License Applications (BLAs) for AVT02, a proposed high-concentration, interchangeable biosimilar to Humira® (adalimumab) Management will conduct a business update conference call and live webcast on Friday, May 19, 2023, at 8:00 am ET (12:00 pm GMT) REYKJAVIK, Iceland, May 19, 2023 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development...

Day: May 19, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice